(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 January 2007 (18.01.2007)

PCT

(10) International Publication Number
WO 2007/009064 A2

(51) International Patent Classification:
A61K 39/395 (2006.01) *A61K 48/00* (2006.01)

(21) International Application Number:
PCT/US2006/027386

(22) International Filing Date: 11 July 2006 (11.07.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/698,517 11 July 2005 (11.07.2005) US

(71) Applicant *(for all designated States except US)*: **MACROGENICS, INC.** [US/US]; 1500 East Gude Drive, Rockville, MD 20850-5307 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **KOENIG, Scott** [US/US]; 10901 Ralston Road, Rockville, MD 20852 (US). **WILDER, Ronald** [US/US]; 7508 Tarpley Drive, Rockville, MD 20855 (US). **BONVINI, Ezio** [US/US]; 2 Shetland Court, Rockville, MD 20851 (US). **JOHNSON, Leslie, S.** [US/US]; 4411 Poplar Hill Road, Darnestown, MD 20874 (US).

(74) Agents: **INSOGNA, Anthony, M.** et al.; JONES DAY, 222 East 41st Street, New York, NY 10017-6702 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS USING IMMUNOSUPPRESSIVE MONOCLONAL ANTIBODIES WITH REDUCED TOXICITY

```
          1       10        20        30        40
Okt3v1 QIVLTQSPAIMSASPGEKVTMTCSASS-SVSYMNWYQQKS
REI    DIQMTQSPSSLSASVGDRVTITCQASQDIIKYLNWYQQTP
gLA    ......................SA.S-SVS.M.......
gLC    ......................SA.S-SVS.M.......

                50        60        70        80
Okt3v1 GTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEA
REI    GKAPKLLIYEASNLQAGVPSRFSGSGSGTDYTFTISSLQP
gLA    .........DT.K.AS........................
gLC    .....RW..DT.K.AS........................

                90       100     108
Okt3v1 EDAATYYCQQWSSNPFTFGSGTKLEINR (SEQ ID NO:1)
REI    EDIATYYCQQYQSLPYTFGQGTKLQITR (SEQ ID NO:2)
gLA    ..........WS.N.F............ (SEQ ID NO:3)
gLC    ..........WS.N.F............ (SEQ ID NO:4)
```

(57) Abstract: The present invention provides methods of treating, preventing or ameliorating the symptoms of T cell-mediated immunological diseases, particularly autoimmune diseases, through the use of anti-CD3 antibodies. In particular, the methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor/alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders. Additionally, the invention provides for modification of the anti-CD3 antibodies such that they exhibit reduced or eliminated effector function and T cell activation as compared to non- modified anti-CD3 antibodies.

WO 2007/009064 A2